Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, E[Chang, Eugene] | - |
dc.contributor.author | Park, CY[Park, Cheol-Young] | - |
dc.contributor.author | Park, SW[Park, Sung Woo] | - |
dc.date.accessioned | 2021-08-04T11:03:29Z | - |
dc.date.available | 2021-08-04T11:03:29Z | - |
dc.date.created | 2016-08-06 | - |
dc.date.issued | 2013-11 | - |
dc.identifier.issn | 2040-1116 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/58813 | - |
dc.description.abstract | The prevalence of metabolic syndrome, obesity and insulin resistance has become an epidemic in the world. A strong association exists between metabolic syndrome and non-alcoholic fatty liver disease (NAFLD), though the etiology of NAFLD is still unclear. This close association leads to numerous clinical studies to investigate the effects of insulin sensitizers, thiazolidinediones (TZDs), on hepatic fat accumulation. Thiazolidinediones affect glucose and lipid metabolism in insulin-sensitive tissues, which in turn reduces the lipid content in the liver by modulating several mediators. In the present review, we discuss key modulators - adiponectin and sirtulin-adenosine monophosphate activated protein kinase signaling - as the mechanisms responsible for NAFLD related to metabolic syndrome. | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.subject | TYPE-2 DIABETES-MELLITUS | - |
dc.subject | ACTIVATED PROTEIN-KINASE | - |
dc.subject | PLACEBO-CONTROLLED TRIAL | - |
dc.subject | PLASMA ADIPONECTIN LEVELS | - |
dc.subject | GLUCAGON-LIKE PEPTIDE-1 | - |
dc.subject | RECEPTOR-GAMMA AGONIST | - |
dc.subject | PEROXISOME-PROLIFERATOR | - |
dc.subject | RISK-FACTORS | - |
dc.subject | NONDIABETIC SUBJECTS | - |
dc.subject | HEPATIC-DYSFUNCTION | - |
dc.title | Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chang, E[Chang, Eugene] | - |
dc.contributor.affiliatedAuthor | Park, CY[Park, Cheol-Young] | - |
dc.contributor.affiliatedAuthor | Park, SW[Park, Sung Woo] | - |
dc.identifier.doi | 10.1111/jdi.12107 | - |
dc.identifier.scopusid | 2-s2.0-84888439070 | - |
dc.identifier.wosid | 000327442200002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF DIABETES INVESTIGATION, v.4, no.6, pp.517 - 524 | - |
dc.relation.isPartOf | JOURNAL OF DIABETES INVESTIGATION | - |
dc.citation.title | JOURNAL OF DIABETES INVESTIGATION | - |
dc.citation.volume | 4 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 517 | - |
dc.citation.endPage | 524 | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | TYPE-2 DIABETES-MELLITUS | - |
dc.subject.keywordPlus | ACTIVATED PROTEIN-KINASE | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | PLASMA ADIPONECTIN LEVELS | - |
dc.subject.keywordPlus | GLUCAGON-LIKE PEPTIDE-1 | - |
dc.subject.keywordPlus | RECEPTOR-GAMMA AGONIST | - |
dc.subject.keywordPlus | PEROXISOME-PROLIFERATOR | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | NONDIABETIC SUBJECTS | - |
dc.subject.keywordPlus | HEPATIC-DYSFUNCTION | - |
dc.subject.keywordAuthor | Insulin resistance | - |
dc.subject.keywordAuthor | Non-alcoholic fatty liver disease | - |
dc.subject.keywordAuthor | Thiazolidinediones | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.